vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
WESBANCO INC is the larger business by last-quarter revenue ($257.2M vs $177.4M, roughly 1.5× Pacira BioSciences, Inc.). WESBANCO INC runs the higher net margin — 34.5% vs 1.6%, a 32.8% gap on every dollar of revenue. Over the past eight quarters, WESBANCO INC's revenue compounded faster (31.9% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
PCRX vs WSBC — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $257.2M |
| Net Profit | $2.9M | $88.6M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | — |
| Net Margin | 1.6% | 34.5% |
| Revenue YoY | 5.0% | — |
| Net Profit YoY | — | 54.4% |
| EPS (diluted) | $0.07 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $257.2M | ||
| Q4 25 | $196.9M | $265.6M | ||
| Q3 25 | $179.5M | $261.6M | ||
| Q2 25 | $181.1M | $260.7M | ||
| Q1 25 | $168.9M | $193.2M | ||
| Q4 24 | $187.3M | $162.9M | ||
| Q3 24 | $168.6M | $150.8M | ||
| Q2 24 | $178.0M | $147.9M |
| Q1 26 | $2.9M | $88.6M | ||
| Q4 25 | — | $91.1M | ||
| Q3 25 | $5.4M | $83.6M | ||
| Q2 25 | $-4.8M | $57.4M | ||
| Q1 25 | $4.8M | $-9.0M | ||
| Q4 24 | — | $49.6M | ||
| Q3 24 | $-143.5M | $37.3M | ||
| Q2 24 | $18.9M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 43.2% | ||
| Q3 25 | 3.5% | 39.5% | ||
| Q2 25 | 4.7% | 27.2% | ||
| Q1 25 | 1.2% | -5.0% | ||
| Q4 24 | 13.2% | 38.0% | ||
| Q3 24 | -82.8% | 29.7% | ||
| Q2 24 | 15.9% | 23.7% |
| Q1 26 | 1.6% | 34.5% | ||
| Q4 25 | — | 34.3% | ||
| Q3 25 | 3.0% | 31.9% | ||
| Q2 25 | -2.7% | 22.0% | ||
| Q1 25 | 2.8% | -4.7% | ||
| Q4 24 | — | 30.5% | ||
| Q3 24 | -85.1% | 24.7% | ||
| Q2 24 | 10.6% | 19.5% |
| Q1 26 | $0.07 | $0.88 | ||
| Q4 25 | $0.05 | $0.97 | ||
| Q3 25 | $0.12 | $0.84 | ||
| Q2 25 | $-0.11 | $0.57 | ||
| Q1 25 | $0.10 | $-0.15 | ||
| Q4 24 | $0.38 | $0.72 | ||
| Q3 24 | $-3.11 | $0.54 | ||
| Q2 24 | $0.39 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $4.1B |
| Total Assets | $1.2B | $27.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $956.1M | ||
| Q3 25 | $246.3M | $1.0B | ||
| Q2 25 | $445.9M | $1.2B | ||
| Q1 25 | $493.6M | $1.1B | ||
| Q4 24 | $484.6M | $568.1M | ||
| Q3 24 | $453.8M | $620.9M | ||
| Q2 24 | $404.2M | $486.8M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | $4.1B | ||
| Q4 25 | $693.1M | $4.0B | ||
| Q3 25 | $727.2M | $4.1B | ||
| Q2 25 | $757.8M | $3.8B | ||
| Q1 25 | $798.5M | $3.8B | ||
| Q4 24 | $778.3M | $2.8B | ||
| Q3 24 | $749.6M | $2.8B | ||
| Q2 24 | $879.3M | $2.5B |
| Q1 26 | $1.2B | $27.5B | ||
| Q4 25 | $1.3B | $27.7B | ||
| Q3 25 | $1.3B | $27.5B | ||
| Q2 25 | $1.5B | $27.6B | ||
| Q1 25 | $1.6B | $27.4B | ||
| Q4 24 | $1.6B | $18.7B | ||
| Q3 24 | $1.5B | $18.5B | ||
| Q2 24 | $1.6B | $18.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
